(Q45361595)

13 December 2017

title

Comparison of the efficacies of lamivudine versus entecavir in patients with hepatitis B virus-related decompensated cirrhosis (English)

1 reference

13 December 2017

0 references

1 reference

1 reference

1 reference

1

1 reference

13 December 2017

Yeon Seok Seo

2

1 reference

13 December 2017

Eileen Yoon

3

1 reference

13 December 2017

Tae Hyung Kim

4

1 reference

13 December 2017

Dong Jin Kim

5

1 reference

13 December 2017

Hyun Seok Kang

6

1 reference

13 December 2017

Eun Suk Jung

7

1 reference

13 December 2017

Jeong Han Kim

8

1 reference

13 December 2017

Hyonggin An

9

1 reference

13 December 2017

Ji Hoon Kim

10

1 reference

13 December 2017

Hyung Joon Yim

11

1 reference

13 December 2017

Jong Eun Yeon

12

1 reference

13 December 2017

Hong Sik Lee

13

1 reference

13 December 2017

Kwan Soo Byun

14

1 reference

13 December 2017

Soon Ho Um

15

1 reference

13 December 2017

Chang Duck Kim

16

1 reference

13 December 2017

Ho Sang Ryu

17

1 reference

13 December 2017

publication date

17 November 2011

1 reference

13 December 2017

1 reference

13 December 2017

volume

32

1 reference

13 December 2017

issue

4

1 reference

13 December 2017

page(s)

656-664

1 reference

Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study

13 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02676.X

Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02676.X

Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02676.X

Lamivudine for patients with chronic hepatitis B and advanced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02676.X

Course of disease and survival after onset of decompensation in hepatitis B virus-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02676.X

Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02676.X

Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02676.X

Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02676.X

A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02676.X

Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02676.X

Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02676.X

Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02676.X

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02676.X

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02676.X

Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02676.X

Transection of the oesophagus for bleeding oesophageal varices

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02676.X

Model for end-stage liver disease (MELD) and allocation of donor livers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02676.X

Hepatitis B virus-related cirrhosis: natural history and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02676.X

Timing of lamivudine administration according to Child class in patients with decompensated cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02676.X

Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02676.X

Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02676.X

Serum cystatin C level is a good prognostic marker in patients with cirrhotic ascites and normal serum creatinine levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02676.X

Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02676.X

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02676.X

Adefovir dipivoxil for wait-listed and post–liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02676.X

10.1111/J.1478-3231.2011.02676.X

21 January 2018

Identifiers

DOI

1 reference

release_i7mozptanzh5hlqyixns2wkpcy

13 December 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/i7mozptanzh5hlqyixns2wkpcy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference